Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03409016 · ClinicalTrials.gov registry record
Biomarkers of Immune-Related Toxicity
A clinical trial of Cancer and Metastatic Cancer, sponsored by University of Colorado, Denver.
- Active
- Registry status
- 69
- Enrollment target
- 1
- Study location
NCT03409016 is a study of Cancer and Metastatic Cancer that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 69 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03409016, a study of Cancer and Metastatic Cancer, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, correlative pilot study evaluating potential biomarkers predictive of immune-related adverse events associated with immune checkpoint inhibitor therapy.
Conditions Studied
Interventions
- OTHER Blood Testing
Study Locations (1)
Colorado
- University of Colorado Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2026-05-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03409016
The ClinicalTrials.gov registry entry for NCT03409016 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood Testing is the first listed.
NCT03409016 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03409016 about?
NCT03409016 is a clinical study titled "Biomarkers of Immune-Related Toxicity". This is a single-center, correlative pilot study evaluating potential biomarkers predictive of immune-related adverse events associated with immune checkpoint inhibitor therapy.
What is the current status of trial NCT03409016?
This trial is currently active not recruiting. The enrollment target is 69 participants. The study started on 2018-04-18. Estimated completion is 2026-05-28.
What conditions does trial NCT03409016 study?
This clinical trial studies the following conditions: Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT03409016?
The interventions under investigation include: Blood Testing (OTHER).
Who is sponsoring clinical trial NCT03409016?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03409016 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.